GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Albany Molecular Research Inc (NAS:AMRI) » Definitions » Beneish M-Score

Albany Molecular Research (Albany Molecular Research) Beneish M-Score : 0.00 (As of Apr. 26, 2024)


View and export this data going back to 1999. Start your Free Trial

What is Albany Molecular Research Beneish M-Score?

The zones of discrimination for M-Score is as such:

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator.
An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

The historical rank and industry rank for Albany Molecular Research's Beneish M-Score or its related term are showing as below:

During the past 13 years, the highest Beneish M-Score of Albany Molecular Research was 0.00. The lowest was 0.00. And the median was 0.00.


Albany Molecular Research Beneish M-Score Historical Data

The historical data trend for Albany Molecular Research's Beneish M-Score can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Albany Molecular Research Beneish M-Score Chart

Albany Molecular Research Annual Data
Trend Dec07 Dec08 Dec09 Dec10 Dec11 Dec12 Dec13 Dec14 Dec15 Dec16
Beneish M-Score
Get a 7-Day Free Trial Premium Member Only Premium Member Only -2.60 -2.71 -1.02 -2.29 -2.61

Albany Molecular Research Quarterly Data
Sep12 Dec12 Mar13 Jun13 Sep13 Dec13 Mar14 Jun14 Sep14 Dec14 Mar15 Jun15 Sep15 Dec15 Mar16 Jun16 Sep16 Dec16 Mar17 Jun17
Beneish M-Score Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -2.73 -2.34 -2.61 -2.46 -2.38

Competitive Comparison of Albany Molecular Research's Beneish M-Score

For the Biotechnology subindustry, Albany Molecular Research's Beneish M-Score, along with its competitors' market caps and Beneish M-Score data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Albany Molecular Research's Beneish M-Score Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Albany Molecular Research's Beneish M-Score distribution charts can be found below:

* The bar in red indicates where Albany Molecular Research's Beneish M-Score falls into.



Albany Molecular Research Beneish M-Score Calculation

The M-score was created by Professor Messod Beneish. Instead of measuring the bankruptcy risk (Altman Z-Score) or business trend (Piotroski F-Score), M-score can be used to detect the risk of earnings manipulation. This is the original research paper on M-score.

The M-Score Variables:

The M-score of Albany Molecular Research for today is based on a combination of the following eight different indices:

M=-4.84+0.92 * DSRI+0.528 * GMI+0.404 * AQI+0.892 * SGI+0.115 * DEPI
=-4.84+0.92 * 0.9181+0.528 * 1.2194+0.404 * 0.9434+0.892 * 1.4885+0.115 * 0.782
-0.172 * SGAI+4.679 * TATA-0.327 * LVGI
-0.172 * 0.9924+4.679 * -0.067326-0.327 * 1.0807
=-2.39

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

This Year (Jun17) TTM:Last Year (Jun16) TTM:
Total Receivables was $147.6 Mil.
Revenue was 172.932 + 163.822 + 191.322 + 152.738 = $680.8 Mil.
Gross Profit was 41.217 + 41.044 + 38.736 + 29.252 = $150.2 Mil.
Total Current Assets was $403.9 Mil.
Total Assets was $1,242.4 Mil.
Property, Plant and Equipment(Net PPE) was $362.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $68.5 Mil.
Selling, General, & Admin. Expense(SGA) was $141.7 Mil.
Total Current Liabilities was $592.7 Mil.
Long-Term Debt & Capital Lease Obligation was $195.6 Mil.
Net Income was -10.247 + -10.692 + -15.411 + -23.425 = $-59.8 Mil.
Non Operating Income was -0.633 + -0.793 + 5.93 + -0.549 = $4.0 Mil.
Cash Flow from Operations was 14.93 + -6.41 + 21.407 + -10.013 = $19.9 Mil.
Total Receivables was $108.0 Mil.
Revenue was 120.81 + 105.579 + 126.412 + 104.579 = $457.4 Mil.
Gross Profit was 38.596 + 26.216 + 33.896 + 24.375 = $123.1 Mil.
Total Current Assets was $256.7 Mil.
Total Assets was $806.5 Mil.
Property, Plant and Equipment(Net PPE) was $222.0 Mil.
Depreciation, Depletion and Amortization(DDA) was $31.6 Mil.
Selling, General, & Admin. Expense(SGA) was $95.9 Mil.
Total Current Liabilities was $102.7 Mil.
Long-Term Debt & Capital Lease Obligation was $370.8 Mil.




1. DSRI = Days Sales in Receivables Index

Measured as the ratio of Revenue in Total Receivables in year t to year t-1.

A large increase in DSR could be indicative of revenue inflation.

DSRI=(Receivables_t / Revenue_t) / (Receivables_t-1 / Revenue_t-1)
=(147.629 / 680.814) / (108.03 / 457.38)
=0.216842 / 0.236193
=0.9181

2. GMI = Gross Margin Index

Measured as the ratio of gross margin in year t-1 to gross margin in year t.

Gross margin has deteriorated when this index is above 1. A firm with poorer prospects is more likely to manipulate earnings.

GMI=GrossMargin_t-1 / GrossMargin_t
=(GrossProfit_t-1 / Revenue_t-1) / (GrossProfit_t / Revenue_t)
=(123.083 / 457.38) / (150.249 / 680.814)
=0.269104 / 0.22069
=1.2194

3. AQI = Asset Quality Index

AQI is the ratio of asset quality in year t to year t-1.

Asset quality is measured as the ratio of non-current assets other than Property, Plant and Equipment to Total Assets.

AQI=(1 - (CurrentAssets_t + PPE_t) / TotalAssets_t) / (1 - (CurrentAssets_t-1 + PPE_t-1) / TotalAssets_t-1)
=(1 - (403.912 + 362.036) / 1242.374) / (1 - (256.653 + 222.011) / 806.506)
=0.38348 / 0.406497
=0.9434

4. SGI = Sales Growth Index

Ratio of Revenue in year t to sales in year t-1.

Sales growth is not itself a measure of manipulation. However, growth companies are likely to find themselves under pressure to manipulate in order to keep up appearances.

SGI=Sales_t / Sales_t-1
=Revenue_t / Revenue_t-1
=680.814 / 457.38
=1.4885

5. DEPI = Depreciation Index

Measured as the ratio of the rate of Depreciation, Depletion and Amortization in year t-1 to the corresponding rate in year t.

DEPI greater than 1 indicates that assets are being depreciated at a slower rate. This suggests that the firm might be revising useful asset life assumptions upwards, or adopting a new method that is income friendly.

DEPI=(Depreciation_t-1 / (Depreciaton_t-1 + PPE_t-1)) / (Depreciation_t / (Depreciaton_t + PPE_t))
=(31.567 / (31.567 + 222.011)) / (68.542 / (68.542 + 362.036))
=0.124486 / 0.159186
=0.782

Note: If the Depreciation, Depletion and Amortization data is not available, we assume that the depreciation rate is constant and set the Depreciation Index to 1.

6. SGAI = Sales, General and Administrative expenses Index

The ratio of Selling, General, & Admin. Expense(SGA) to Sales in year t relative to year t-1.

SGA expenses index > 1 means that the company is becoming less efficient in generate sales.

SGAI=(SGA_t / Sales_t) / (SGA_t-1 /Sales_t-1)
=(141.687 / 680.814) / (95.92 / 457.38)
=0.208114 / 0.209716
=0.9924

7. LVGI = Leverage Index

The ratio of total debt to Total Assets in year t relative to yeat t-1.

An LVGI > 1 indicates an increase in leverage

LVGI=((LTD_t + CurrentLiabilities_t) / TotalAssets_t) / ((LTD_t-1 + CurrentLiabilities_t-1) / TotalAssets_t-1)
=((195.591 + 592.659) / 1242.374) / ((370.798 + 102.715) / 806.506)
=0.634471 / 0.587117
=1.0807

8. TATA = Total Accruals to Total Assets

Total accruals calculated as the change in working capital accounts other than cash less depreciation.

TATA=(IncomefromContinuingOperations_t - CashFlowsfromOperations_t) / TotalAssets_t
=(NetIncome_t - NonOperatingIncome_t - CashFlowsfromOperations_t) / TotalAssets_t
=(-59.775 - 3.955 - 19.914) / 1242.374
=-0.067326

An M-Score of equal or less than -1.78 suggests that the company is unlikely to be a manipulator. An M-Score of greater than -1.78 signals that the company is likely to be a manipulator.

Albany Molecular Research has a M-score of -2.39 suggests that the company is unlikely to be a manipulator.


Albany Molecular Research Beneish M-Score Related Terms

Thank you for viewing the detailed overview of Albany Molecular Research's Beneish M-Score provided by GuruFocus.com. Please click on the following links to see related term pages.


Albany Molecular Research (Albany Molecular Research) Business Description

Traded in Other Exchanges
N/A
Address
Albany Molecular Research provides research services to pharmaceutical, biotechnology, and chemical companies. The company offers services like design and modification of potential lead compounds, purification technique development, quality control, bulk ingredient stability studies, and regulatory documentation preparation. The company has entered into collaborative agreements with companies like Eli Lilly and Cambrex. Albany's acquisition of Organichem provided the company with commercial manufacturing capabilities.
Executives
Anthony J Maddaluna director PFIZER INC. ATTN CORPORATE SECRETARY, 235 RAST 42ND STREET, NEW YORK NY 10017
Felicia I Ladin officer: SVP, Treasurer & CFO 26 CORPORATE CIRCLE, ALBANY NY 12203
David H Deming director C/O BETTER FOR YOU WELLNESS, INC., 1349 EAST BROAD ST, COLUMBUS OH 43205
William S Marth director, officer: President and CEO 236 GROVE STREET, WELLESLEY MA 02482
Lori M. Henderson officer: SVP, Secretary & Gen Counsel MOLDFLOW CORP, 430 BOSTON POST ROAD, WAYLAND MA 01778
Una S Ryan director 329 HAMMOND STREET, CHESTNUT HILL MA 02467
Veronica Gh Jordan director C/O ALBANY MOLECULAR RESEARCH, INC., 26 CORPORATE CIRCLE, ALBANY NY 12212-5098
Gabriel Leung director C/O PERNIX THERAPEUTICS HOLDINGS, INC., 10 NORTH PARK PLACE, SUITE 201, MORRISTOWN NJ 07960
Michael A Luther officer: Senior VP, Discovery Services 21 CORPORATE CIRCLE, ALBANY NY 12203
Mark T Frost officer: Chief Financial Officer 21 CORPORATE CIRCLE, PO BOX 15098, ALBANY NY 12033-5098
David P Waldek officer: Chief Financial Officer ALBANY MOLECULAR RESEARCH INC, 21 CORPORATE CIRCLE PO BOX 15098, ALBANY NY 12212-5098

Albany Molecular Research (Albany Molecular Research) Headlines

No Headlines